drugset / Trial / NCT00917267

A Study to Examine the Effects of Exenatide Once-Weekly Injection on Glucose Control and Safety in Asian Subjects

NCT00917267

Phase 3 Completed 691 enrolled AstraZeneca Eli Lilly and Company · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

Previous studies have suggested that a once-weekly formulation of exenatide may provide sustained glycemic control. These previous studies of exenatide once weekly have been conducted in non-Asian populations, so this study has been developed to support the local regulatory requirements of China, Korea, Japan, India, and Taiwan.

Timeline

Start
2009-07
Primary completion
2010-09
Completion
2011-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Exenatide Peptide 10 ug Subcutaneous
Subject Exenatide Peptide 2 mg Subcutaneous